Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability, Safety and Pharmacokinetic Characteristics of SHR-1802 in Patients With Advanced Malignancy: a Phase I Clinical Study

NCT04414150 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT04414150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04414150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability, Safety and Pharmacokinetic Characteristics of SHR-1802 in Patients With Advanced Malignancy: a Phase I Clinical Study
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 17, 2020
Completion date
March 15, 2022
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant tumours